Bioretec Q2'25: Slower sales development than expected

Bioretec's weak Q2 earnings were a disappointment compared to expectations. The company's revenue and gross margin % decreased sharply, and the simultaneous increase in operational costs doubled the operating loss. Bioretec's interim CEO Sarah Hubar-Fisher provides more details in an interview with analyst Antti Siltanen.

Topics

00:00 Introduction

00:13 Q2 summary

02:18 Negative revenue impact of ended Spartan Medical distribution deal

03:06 Weak performance in Europe and the United States

05:46 Status of country-specific processes in terms of RemeOs sales

06:55 Expectations for the rest of the year

08:48 Reasons to focus more on sales agent model

09:43 Main bottlenecks and obstacles for increasing sales

11:11 Indication expansion in US

12:09 RemeOs's sales outlook in the United States

13:11 Sales agent model

14:50 Opex level

15:48 Increased working capital level

16:50 R&D pipeline

18:11 Development of single-use tools

19:50 Reimbursements

21:00 Learnings in RemeOs’s commercialization

22:16 Final words